Back to Directory
Last Updated: 05/05/2026

AviadoBio

London
Founded 2019
AAV gene therapies for neurodegenerative diseases including FTD and ALS

AviadoBio is a clinical-stage gene therapy company developing AAV-based treatments for neurodegenerative diseases.

Its lead programme, AVB-101, is in a Phase 1/2 trial for frontotemporal dementia caused by GRN gene mutations, delivering a functional copy of the GRN gene via intrathalamic infusion to restore progranulin levels.

The broader pipeline spans retinal dystrophies and Alzheimer's disease. AVB-101 holds FDA Fast Track and orphan designations.

BiopharmaCell & Gene TherapyNeurology
Neurodegenerative DiseaseRare Diseases

Is this your company?

Claim this page to receive a verified badge and keep your profile up to date.

Claim page

Company Notes

Member of